|
Pathogen (Target Population)
|
Type of Vaccine
|
Time to Licensure (years)
|
Time After Licensure to Adoption (years)
|
Total Time to Steady State of Vaccine Use (years)
|
Delay of Vaccination Benefits (years)
|
Total Time to SteadyState Yield of Benefits (years)
|
|
Dengue virus
(Infants and children in endemic areas; travelers to endemic areas)
|
Attenuated live vector virus containing gene for broadly cross-reacting protective antigen
|
10
|
2
|
12
|
5
|
17
|
|
Escherichia coli
(enterotoxigenic)
(Infants < 6 months)
|
A combination of purified colonization factor antigens and possibly other antigens
|
10
|
2
|
12
|
1
|
13
|
|
Genetically engineered attenuated strains
|
10
|
2
|
12
|
1
|
13
|
|
Hemophilus influenzae type b
(Infants)
|
Conjugated polysaccharide
|
3
|
5
|
8
|
2
|
10
|
|
Hepatitis A virus
(Susceptibles of all ages; routine for preschool children)
|
Attenuated live virus
|
4
|
5
|
9
|
2
|
11
|
|
Polypeptide recombinant vaccine produced in yeast
|
5
|
5
|
10
|
2
|
12
|
|
Hepatitis B virus
(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous With other vaccinations, at earliest possible age)
|
Polypeptide produced by recombinant DNA technology
|
1
|
2
|
3
|
30
|
33
|
|
Japanese encephalitis virus
(Children in epidemic and endemic areas; foreign visitors to epidemic regions)
|
Inactivated virus produced in cell culture
|
7
|
2.5
|
9.5
|
7
|
16.5
|
